Targeted drug olaparib tested in breast cancer patients with DNA repair flaws
NCT ID NCT03344965
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tests the drug olaparib in 114 people with metastatic breast cancer whose tumors have mutations in certain DNA repair genes (like BRCA1, BRCA2, ATM, PALB2, and others). Olaparib is a PARP inhibitor that may kill cancer cells by blocking their ability to fix damaged DNA. The study aims to see how many patients respond to the treatment and how safe it is.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olaparib (a PARP inhibitor drug taken as tablets)
- What this could lead to
- If successful, this could provide a targeted treatment option for metastatic breast cancer patients with certain inherited or tumor-acquired DNA repair gene mutations.
- What could go wrong
- This is a mid-stage trial with a moderate number of participants. The drug may not shrink tumors or improve survival for all mutation types, and side effects like fatigue, nausea, or blood count changes are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATM GENE MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02115, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University
Durham, North Carolina, 27708, United States
-
Indiana University
Indianapolis, Indiana, 46202, United States
-
Johns Hopkins University
Baltimore, Maryland, 21218, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Memorial Sloan Kettering Cancer Center Basking Ridge
Basking Ridge, New Jersey, 07920, United States
-
Memorial Sloan Kettering Cancer Center Bergen
Montvale, New Jersey, 07645, United States
-
Memorial Sloan Kettering Cancer Center Commack
Commack, New York, 11725, United States
-
Memorial Sloan Kettering Cancer Center Monmouth
Middletown, New Jersey, 07748, United States
-
Memorial Sloan Kettering Cancer Center Nassau
Uniondale, New York, 11553, United States
-
Memorial Sloan Kettering Cancer Center Westchester
East White Plains, New York, 10604, United States
-
UPMC Hillman Cancer Center - Erie
Erie, Pennsylvania, 16505, United States
-
University of Alabama at Birmingham
Birmingham, Alabama, 35294, United States
-
University of California, San Francisco
San Francisco, California, 94143, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
-
University of Pittsburgh
Pittsburgh, Pennsylvania, 15260, United States
-
University of Washington Fred Hutchinson Cancer Care
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can sound waves replace the scalpel for breast tumors?
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Could a bank of breast cancer samples unlock new treatments?
- Could a personal coach at home boost energy for cancer patients?